PDF File
- FR
- EN
PDF File
PDF File
SCOR delivers a strong performance for the first quarter 2014 with a net income of EUR 135 million, up 21.6%
6 May 2014, Paris
SCOR Global P&C’s April renewals.
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets.
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
The Deepwater Horizon accident has led to a re-evaluation of deepwater drilling procedures.
Availability of the documents relating to the 2014 combined general shareholders' meeting.
Pagination